Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial

European Journal of Haematology

Volumn 92, Issue 3, 2014, Pages 249-255

  Spackman, Eldon ^a   Sculpher, Mark ^a   Howard, Jo ^b   Malfroy, Moira ^c   Llewelyn, Charlotte ^c   Choo, Louise ^d   Hodge, Renate ^c   Johnson, Tony ^d   Rees, David C ^e   Fijnvandraat, Karin ^f   Kirby Allen, Melanie ^g   Davies, Sally ^h   Williamson, Lorna ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h Department of Health ^*  (United Kingdom)

Author keywords

Cost; Cost effectiveness; Quality adjusted life years; Sickle cell disease; Transfusion; Transfusion Alternatives Preoperatively in Sickle Cell Disease trial

Indexed keywords

COST; COST-EFFECTIVENESS; QUALITY-ADJUSTED LIFE YEARS; SICKLE CELL DISEASE; TRANSFUSION; TRANSFUSION ALTERNATIVES PREOPERATIVELY IN SICKLE CELL DISEASE TRIAL;

AGED; ALGORITHMS; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84894229033     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12232     Document Type: Article

References (19)

1. Buck J, Casbard A, Llewelyn C, Johnson T, Davies S, Williamson L. Preoperative transfusion in sickle cell disease: a survey of practice in England. Eur J Haematol 2005;75:14-21.
2. Hirst C, Williamson L. Preoperative blood transfusions for sickle cell disease. Cochrane Database Syst Rev 2012;1:CD003149.
3. Howard J, Malfroy M, Llewelyn C, et al. The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013;381:930-8.
4. Kind P, Brooke R, Rabind R. EQ-5D Concepts and Methods: A Developmental History. Amsterdam: Springer, 2005.
5. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
6. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461-75.
7. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96.
8. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006;10:1-288.
9. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001;357:680-3.
10. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease. Blood 1997;89:1787-92.
11. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the Estimation of the NICE Cost Effectiveness Threshold. Centre for Health Economics: University of York, York, 2013.
12. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308.
13. NICE, 2008. Guide to the methods of technology appraisal.
14. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, Pegelow C, Abboud M, Ohene-Frempong K, Iyer RV. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The preoperative transfusion in sickle cell disease study group. N Engl J Med 1995;333:206-13.
15. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010;32:2478-93.
16. NHS Blood and Transplant, 2011. Price List: Blood component products/services for 2010/2011.
17. Department of Health, 2011. NHS reference costs 2010-2011.
18. McKenna C, Wade R, Faria R, Yang H, Stirk L, Gummerson N, Sculpher M, Woolacott N. EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. Health Technol Assess 2012;16:1-181.
19. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xii, 1-210.